Search results for "RHAG"

showing 10 items of 593 documents

Circulation and diagnostics of Puumala virus in Norway: nephropatia epidemica incidence and rodent population dynamics.

2017

Hantaviruses pose a public health concern worldwide causing haemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Puumala virus (PUUV) is the most prevalent hantavirus in Central and Northern Europe, and causes a mild form of HFRS, also known as nephropathia epidemica (NE). In nature, the main host of PUUV is the bank vole (Myodes glareolus), and transmission to humans occurs through inhalation of aerosols from rodent excreta. Nephropathia epidemica is particularly prevalent in Nordic countries, however, few studies of PUUV have been performed in Norway. The aim of this study was to analyse the dynamics of PUUV in Norway and compare with bank vole population…

0301 basic medicineMaleSerumRodentanimal diseasesvirusesPopulation DynamicsSequence HomologyPolymerase Chain ReactionPuumala virusImmunology and AllergyMedicineCluster AnalysisHaemorrhagic feverChildPhylogenyAged 80 and overeducation.field_of_studybiologyArvicolinaeNorwayIncidence (epidemiology)Incidencevirus diseasesGeneral MedicineMiddle AgedChild PreschoolHemorrhagic Fever with Renal SyndromePuumala virusFemaleTopography MedicalSeasonsMicrobiology (medical)Adultmedicine.medical_specialtyAdolescent030106 microbiologyPopulationHantavirus Pulmonary SyndromeReal-Time Polymerase Chain ReactionPathology and Forensic Medicine03 medical and health sciencesYoung Adultbiology.animalAnimalsHumanseducationAgedHantavirus pulmonary syndromebusiness.industryPublic healthInfant NewbornInfantSequence Analysis DNAbiology.organism_classificationVirologyrespiratory tract diseases030104 developmental biologybusinessAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica
researchProduct

Domain-specific characterisation of early cognitive impairment following spontaneous intracerebral haemorrhage.

2018

Cognitive deficits after spontaneous intracerebral haemorrhage (ICH) are common and result in functional impairment, but few studies have examined deficits across cognitive domains in the subacute phase. This study aims to describe the cognitive profile following acute ICH and explore how cerebral amyloid angiopathy (CAA) may impact performance. We retrospectively reviewed 187 consecutive patients with ICH (mean age 58.9 years, 55.6% male) with available imaging and neuropsychological data (median 12 days after stroke). In our cohort, 84% (n = 158) were impaired in at least one cognitive domain and 65% (n = 122) in two or more domains. Deficits in non-verbal IQ (76.6%), information processi…

0301 basic medicineMalemedicine.medical_specialtyVisual perceptionTime FactorsAudiologyNeuropsychological Tests03 medical and health sciences0302 clinical medicineMedicineHumansCognitive Dysfunctioncardiovascular diseasesCognitive impairmentStrokeCerebral HemorrhageRetrospective Studiesbusiness.industryNeuropsychologyBrainCognitionMiddle Agedmedicine.diseaseExecutive functionsMagnetic Resonance Imaging030104 developmental biologyNeurologyCohortFemaleNeurology (clinical)Cerebral amyloid angiopathybusiness030217 neurology & neurosurgeryJournal of the neurological sciences
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

The fibronectin synergy site re-enforces cell adhesion and mediates a crosstalk between integrin classes

2017

Fibronectin (FN), a major extracellular matrix component, enables integrin-mediated cell adhesion via binding of α5β1, αIIbβ3 and αv-class integrins to an RGD-motif. An additional linkage for α5 and αIIb is the synergy site located in close proximity to the RGD motif. We report that mice with a dysfunctional FN-synergy motif (Fn1syn/syn) suffer from surprisingly mild platelet adhesion and bleeding defects due to delayed thrombus formation after vessel injury. Additional loss of β3 integrins dramatically aggravates the bleedings and severely compromises smooth muscle cell coverage of the vasculature leading to embryonic lethality. Cell-based studies revealed that the synergy site is dispensa…

0301 basic medicineMouseQH301-705.5extracellular matrixScienceExtracellular matrix componentIntegrinHemorrhageGeneral Biochemistry Genetics and Molecular BiologyExtracellular matrixMice03 medical and health sciencesfibronectinAnimalsBiology (General)Cell adhesionRGD motifMice KnockoutGeneral Immunology and MicrobiologybiologyCell adhesion moleculeChemistryGeneral NeuroscienceQRThrombosiscell adhesionCell BiologyGeneral MedicineFibronectinsCell biologyFibronectinCrosstalk (biology)030104 developmental biologymechanosignalingImmunologyintegrinsbiology.proteinMedicineResearch ArticleeLife
researchProduct

Introducing the concept of “CSF-shift edema” in traumatic brain injury

2018

Brain edema after severe traumatic brain injury (TBI) plays an important role in the outcome and survival of injured patients. It is also one of the main targets in the therapeutic approach in the current clinical practice. To date, the pathophysiology of traumatic brain swelling is complex and, being that it is thought to be mainly cytotoxic and vasogenic in origin, not yet entirely understood. However, based on new understandings of the hydrodynamic aspects of cerebrospinal fluid (CSF), an additional mechanism of brain swelling can be considered. An increase in pressure into the subarachnoid space, secondary to traumatic subarachnoid hemorrhage, would result in a rapid shift of CSF from t…

0301 basic medicinePathologymedicine.medical_specialtySubarachnoid hemorrhageTraumatic brain injurybrain edema; cisternostomy; decompressive hemicraniectomy; paravascular pathway; traumatic brain injury; Cellular and Molecular NeuroscienceBrain water03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineCerebrospinal fluidEdemaBrain Injuries TraumaticmedicineHumansparavascular pathwaybrain edemaBrain edemabusiness.industrytraumatic brain injurymedicine.diseasecisternostomyPathophysiology030104 developmental biologymedicine.anatomical_structureSubarachnoid spacemedicine.symptomExtracellular Spacebusinessdecompressive hemicraniectomybrain edema; cisternostomy; decompressive hemicraniectomy; paravascular pathway; traumatic brain injury030217 neurology & neurosurgeryJournal of Neuroscience Research
researchProduct

Jacobsen syndrome and neonatal bleeding: report on two unrelated patients

2021

Abstract Introduction In 1973, Petrea Jacobsen described the first patient showing dysmorphic features, developmental delay and congenital heart disease (atrial and ventricular septal defect) associated to a 11q deletion, inherited from the father. Since then, more than 200 patients have been reported, and the chromosomal critical region responsible for this contiguous gene disorder has been identified. Patients’ presentation We report on two unrelated newborns observed in Italy affected by Jacobsen syndrome (JBS, also known as 11q23 deletion). Both patients presented prenatal and postnatal bleeding, growth and developmental delay, craniofacial dysmorphisms, multiple congenital anomalies, a…

0301 basic medicinePediatricsmedicine.medical_specialtyGenotype-phenotype correlationHeart diseaseGenetic counselingCase ReportIn situ hybridization030105 genetics & heredityPediatricsRJ1-57003 medical and health sciences0302 clinical medicineaCGHJBSmedicineHumansJacobsen Distal 11q Deletion SyndromeJacobsen syndromeCraniofacialGenetic Association StudiesCerebral Hemorrhage11q23 deletionbusiness.industryInfant NewbornEarly diagnosimedicine.diseaseEarly diagnosisPancytopeniaThrombocytopeniaItalyFemalePresentation (obstetrics)business030217 neurology & neurosurgeryComparative genomic hybridizationItalian Journal of Pediatrics
researchProduct

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct

Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation

2015

Unwinding DNA and unleasing inflammation Fighting infections often comes with collateral damage, which sometimes can be deadly. For instance, in septic shock, the overwhelming release of inflammatory mediators drives multi-organ failure. Rialdi et al. now report a potential new therapeutic target for controlling excessive inflammation: the DNA unwinding enzyme topoisomerase I (Top1) (see the Perspective by Pope and Medzhitov). Upon infection, Top1 specifically localizes to the promoters of pathogen-induced genes and promotes their transcription by helping to recruit RNA polymerase II. Pharmacological inhibition of Top1 in a therapeutic setting increased survival in several mouse models of s…

0301 basic medicineTranscription GeneticType IInbred C57BLmedicine.disease_causeSendai virusMicePiperidinesTranscription (biology)Influenza A virusInnate2.1 Biological and endogenous factorsPositive Transcriptional Elongation Factor BAetiologyMultidisciplinaryAzepinesStaphylococcal InfectionsEbolavirusInfectious DiseasesDNA Topoisomerases Type IInfluenza A virusEbolaHost-Pathogen InteractionsPneumonia & InfluenzaRNA Polymerase IImedicine.symptomInfectionTranscriptionStaphylococcus aureusGeneral Science & TechnologyInflammationBiologyVaccine Related03 medical and health sciencesImmune systemGeneticImmunityBiodefenseGeneticsmedicineAnimalsHumansGeneFlavonoidsInflammationInnate immune systemPreventionHEK 293 cellsImmunityInterferon-betaHemorrhagic Fever EbolaTriazolesImmunity InnateMice Inbred C57BLEmerging Infectious DiseasesGood Health and Well BeingHEK293 Cells030104 developmental biologyGene Expression RegulationImmunologyCancer researchHemorrhagic FeverCamptothecinTopoisomerase I InhibitorsTopotecanDNA TopoisomerasesScience
researchProduct

The Unsolved Conundrum of Optimal Blood Pressure Target During Acute Haemorrhagic Stroke: A Comprehensive Analysis

2019

Intracerebral haemorrhage (ICH) is a devastating cerebrovascular disease, which accounts to 15% of all strokes. Among modifiable risk factors for ICH, hypertension is the most frequent. High blood pressure (BP) is detected in more than 75–80% of patients with ICH. Extremely elevated BP has been associated with early hematoma growth, a relatively frequent occur-rence and powerful predictor of poor outcome in patients with spontaneous ICH. On the other hand, excessively low BP might cause cerebral hypoperfusion and ultimately lead to poor outcome. This review will analyse the most important trials that have tried to establish how far should BP be lowered during acute ICH. These trials have de…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaElevated bpClinical Decision-MakingBlood PressureHaemorrhagic stroke03 medical and health sciences0302 clinical medicinePharmacotherapyHematomaRisk FactorsInternal medicineInternal MedicinemedicineHumansIn patientcardiovascular diseasesStrokeAntihypertensive AgentsCerebral HemorrhageSettore MED/14 - NefrologiaCerebral hypoperfusionBlood pressure · Hypertension · Intracerebral haemorrhage · Strokebusiness.industrymedicine.diseaseStrokeTreatment Outcome030104 developmental biologyBlood pressureCardiologySettore MED/26 - NeurologiaCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgery
researchProduct

INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY

2017

PURPOSE To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). METHODS Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. RESULTS The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coheren…

0301 basic medicinemedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabmedicine.medical_treatmentVitrectomy03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectRetinabusiness.industryRetrospective cohort studyGeneral MedicineDiabetic retinopathymedicine.diseaseeye diseasesOphthalmology030104 developmental biologymedicine.anatomical_structureVitreous hemorrhage030221 ophthalmology & optometrysense organsmedicine.symptombusinessmedicine.drugRetina
researchProduct